Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Peripheral Nervous System Diseases 1 Hereditary Sensory and Autonomic Neuropathies 1 Cardiotoxicity 1

Interventions

Doxorubicin 17 Echocardiography 14 Exercise 9 Cyclophosphamide 9 Trastuzumab 8 Dexrazoxane 8 Electrocardiography 7 Razoxane 6 Carvedilol 6 Vincristine 4 Radiotherapy 4 Filgrastim 4 Docetaxel 4 Methotrexate 3 Granulocyte Colony-Stimulating Factor 3 Etoposide 3 Cisplatin 3 Atorvastatin 3 salicylhydroxamic acid 2 sacubitril and valsartan sodium hydrate drug combination 2 empagliflozin 2 dapagliflozin 2 Tablets 2 Social Determinants of Health 2 Silymarin 2 Prednisone 2 Paclitaxel 2 Neoadjuvant Therapy 2 Magnetic Resonance Spectroscopy 2 Leucovorin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Cardiotoxicity × Trimetazidine × Clear all

NCT04939857 2021-06-25

Effect of Trimetazidine on Radiotherapy-induced Heart Damage.

Peking University Third Hospital

Phase 2/3 Unknown

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡